Concurrent Changes in Plasma Phosphorylated Tau 217, Tau PET, and Cognition in Preclinical Alzheimer Disease
Importance: Developing disease-modifying treatments is a priority for Alzheimer disease research. Objective: To determine the potential of plasma phosphorylated tau 217 (p-tau217) and tau positron emission tomography (PET) to assess disease modification in treatment trials. Design, Setting, and Participants: This diagnostic/prognostic study used longitudinal data from the Anti-Amyloid Treatment in
